BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 19466922)

  • 1. Comparison of costs and utilization among buprenorphine and methadone patients.
    Barnett PG
    Addiction; 2009 Jun; 104(6):982-92. PubMed ID: 19466922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment.
    Bell J; Trinh L; Butler B; Randall D; Rubin G
    Addiction; 2009 Jul; 104(7):1193-200. PubMed ID: 19563562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
    Turner BJ; Laine C; Lin YT; Lynch K
    Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03.
    de Wet CJ; Reed LJ; Bearn J
    Addiction; 2005 Apr; 100(4):495-9. PubMed ID: 15784064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.
    Stein BD; Gordon AJ; Sorbero M; Dick AW; Schuster J; Farmer C
    Drug Alcohol Depend; 2012 Jun; 123(1-3):72-8. PubMed ID: 22093488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost and utilization outcomes of opioid-dependence treatments.
    Baser O; Chalk M; Fiellin DA; Gastfriend DR
    Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities.
    Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I
    Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study.
    Anchersen K; Clausen T; Gossop M; Hansteen V; Waal H
    Addiction; 2009 Jun; 104(6):993-9. PubMed ID: 19392907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years.
    Gordon AJ; Trafton JA; Saxon AJ; Gifford AL; Goodman F; Calabrese VS; McNicholas L; Liberto J;
    Drug Alcohol Depend; 2007 Oct; 90(2-3):292-6. PubMed ID: 17493771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and social effects of high-dose buprenorphine substitution therapy. Six-month results.
    Lavignasse P; Lowenstein W; Batel P; Constant MV; Jourdain JJ; Kopp P; Reynaud-Maurupt C; Riff B; Videau B; Mucchielli A
    Ann Med Interne (Paris); 2002 May; 153(3 Suppl):1S20-6. PubMed ID: 12218879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linking opioid-dependent hospital patients to drug treatment: Health care use and costs 6 months after randomization.
    Barnett PG; Masson CL; Sorensen JL; Wong W; Hall S
    Addiction; 2006 Dec; 101(12):1797-804. PubMed ID: 17156179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
    Maas J; Barton G; Maskrey V; Pinto H; Holland R
    Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR; Lea T; Ritter A
    Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Buprenorphine or methadone for detoxification of young opioid addicts?].
    Ebner R; Schreiber W; Zierer C
    Psychiatr Prax; 2004 Nov; 31 Suppl 1():S108-10. PubMed ID: 15570521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003-06).
    Marzo JN; Rotily M; Meroueh F; Varastet M; Hunault C; Obradovic I; Zin A
    Addiction; 2009 Jul; 104(7):1233-40. PubMed ID: 19426291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
    Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
    J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.